Physician profile
Robert Otte
NPI 1295798791
$6,666.91
in general payments reported to CMS, 2019-2025
48 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $502 · 2021: $1,278 · 2022: $1,292 · 2023: $1,429 · 2024: $621 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.21 | 2019-2024 | |
| Lilly USA, LLC | $647.99 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $612.65 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $557.87 | 2019-2024 | |
| Amgen INC. | $553.01 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $484.33 | 2019-2024 | Shingrix, Bexsero, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $267.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $208.87 | 2019-2021 | |
| Amarin Pharma, INC. | $199.85 | 2019-2022 | |
| Abbott Laboratories | $165.35 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $142.58 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.61 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $98.50 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.59 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.13 | 2021-2024 | Jardiance |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Otte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.